Bronchodilator Drugs - Morocco | Statista Market Forecast

The Bronchodilator Drugs market in Morocco is expected to witness a significant revenue growth, with projections indicating that it will reach US$17.10m in 2024.
Furthermore, the market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 4.00%, leading to a market volume of US$20.80m by 2029.
When compared to other countries worldwide, it is noteworthy that United States is expected to generate the highest revenue in the Bronchodilator Drugs market, with an estimated amount of US$17.34bn in 2024.
Morocco's bronchodilator drug market is witnessing a surge in demand due to the increasing prevalence of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchitis. In Morocco, the Bronchodilator Drugs market has been experiencing steady growth in recent years.

Customer preferences: In Morocco, the demand for bronchodilator drugs has been increasing due to the rising prevalence of respiratory diseases. Patients are increasingly seeking effective treatments for these conditions, which has led to an increase in demand for bronchodilator drugs. In addition, the availability of these drugs in different forms such as inhalers, nebulizers, and tablets has made them more accessible to patients.

Trends in the market: One of the major trends in the Bronchodilator Drugs market in Morocco is the increasing availability of generic drugs. The availability of generic drugs has made treatment more affordable and accessible to a larger population. In addition, the increasing adoption of combination therapy, which involves the use of two or more drugs to treat respiratory diseases, has also been a major trend in the market.

Local special circumstances: Morocco has a high prevalence of respiratory diseases, with asthma and COPD being the most common. The country has a high level of air pollution, which is a major contributor to the high prevalence of respiratory diseases. In addition, smoking is also a major risk factor for respiratory diseases in Morocco.

Underlying macroeconomic factors: Morocco has been experiencing steady economic growth in recent years, which has led to an increase in healthcare spending. The government has been investing in the healthcare sector, which has led to an improvement in healthcare infrastructure and services. This has also led to an increase in the availability of bronchodilator drugs in the country.In conclusion, the Bronchodilator Drugs market in Morocco has been experiencing steady growth due to the rising prevalence of respiratory diseases and the increasing availability of generic drugs. The adoption of combination therapy has also been a major trend in the market. Morocco's high level of air pollution and smoking rates are local special circumstances that contribute to the high prevalence of respiratory diseases in the country. The steady economic growth in the country and the government's investment in the healthcare sector are underlying macroeconomic factors that have led to an increase in the availability of bronchodilator drugs in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.